Aclaris Therapeutics (ACRS) Lowered to “Sell” at Zacks Investment Research
Zacks Investment Research lowered shares of Aclaris Therapeutics (NASDAQ:ACRS) from a hold rating to a sell rating in a research report sent to investors on Tuesday morning.
According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “
Other research analysts have also recently issued research reports about the stock. Cantor Fitzgerald set a $50.00 price target on shares of Aclaris Therapeutics and gave the company a buy rating in a research report on Tuesday, June 12th. BidaskClub raised shares of Aclaris Therapeutics from a hold rating to a buy rating in a research report on Monday, June 18th. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the company. The company has a consensus rating of Hold and a consensus price target of $43.50.
Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Friday, August 3rd. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.05) by $0.04. Aclaris Therapeutics had a negative net margin of 1,584.99% and a negative return on equity of 49.45%. The business had revenue of $3.68 million during the quarter, compared to analyst estimates of $2.76 million. equities research analysts forecast that Aclaris Therapeutics will post -4.6 EPS for the current fiscal year.
In other news, Director Stephen A. Tullman purchased 6,250 shares of the stock in a transaction dated Wednesday, August 15th. The shares were purchased at an average price of $15.97 per share, with a total value of $99,812.50. Following the transaction, the director now owns 163,757 shares in the company, valued at approximately $2,615,199.29. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Stephen A. Tullman purchased 6,600 shares of the stock in a transaction dated Thursday, August 23rd. The shares were purchased at an average cost of $15.00 per share, for a total transaction of $99,000.00. Following the transaction, the director now owns 170,357 shares in the company, valued at approximately $2,555,355. The disclosure for this purchase can be found here. Insiders own 17.00% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. Royal Bank of Canada boosted its position in shares of Aclaris Therapeutics by 561.0% during the 1st quarter. Royal Bank of Canada now owns 6,517 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 5,531 shares during the last quarter. Bank of Montreal Can acquired a new position in Aclaris Therapeutics in the second quarter valued at about $159,000. Granite Investment Partners LLC acquired a new position in Aclaris Therapeutics in the second quarter valued at about $164,000. Cubist Systematic Strategies LLC lifted its position in Aclaris Therapeutics by 518.4% in the first quarter. Cubist Systematic Strategies LLC now owns 8,361 shares of the biotechnology company’s stock valued at $146,000 after buying an additional 7,009 shares during the last quarter. Finally, CIBC Private Wealth Group LLC acquired a new position in Aclaris Therapeutics in the second quarter valued at about $200,000. 99.75% of the stock is currently owned by hedge funds and other institutional investors.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.